Robert Hershberg Biography and Net Worth

Director of Atai Beckley

Rob Hershberg, M.D., Ph.D., is Co-Founder President, Chief Executive Officer and chairman of the board of directors of HilleVax. Rob is also a Venture Partner with Frazier Healthcare Partners and has been working with Frazier and its portfolio companies as an Entrepreneur-in-Residence, Senior Advisor, and executive for 14 years. He was formerly President and Chief Executive Officer of VentiRx Pharmaceuticals, a Frazier-founded company developing a small molecule therapeutic to activate the immune system against solid tumors which he co-founded while an entrepreneur-in-residence at Frazier. Rob led the company through its transformational partnership with Celgene. He joined Celgene in 2014 to lead their efforts in Immuno-Oncology, was promoted to Executive Vice President and Chief Scientific Officer in 2016 and was subsequently Executive Vice President and Head of Business Development & Global Alliances until the acquisition of Celgene by Bristol-Myers Squibb in 2019. Prior to VentiRx, Rob served as Senior Vice President and Chief Medical Officer of Dendreon Corporation and led clinical development of Provenge, which was approved for metastatic prostate cancer. Before Dendreon, he was Vice President of Medical Genetics at Corixa, a Frazier portfolio company which was acquired by GlaxoSmithKline. Earlier, Rob was an Assistant Professor at Harvard Medical School and an Associate Physician at Brigham and Women’s Hospital in Boston. Rob completed his undergraduate and medical degrees at the University of California, Los Angeles and received his Ph.D. at the Salk Institute for Biological Studies.

What is Robert Hershberg's net worth?: The estimated net worth of Robert Hershberg is at least $489.50 thousand as of July 7th, 2026. Dr. Hershberg owns 100,000 shares of Atai Beckley stock worth more than $489,500 as of July 13th. This net worth evaluation does not reflect any other assets that Dr. Hershberg may own. Learn More about Robert Hershberg's net worth.
How do I contact Robert Hershberg?: The corporate mailing address for Dr. Hershberg and other Atai Beckley executives is c/o Mindspace Krausenstra sse 9-10, Berlin, Berlin 10117. Atai Beckley can also be reached via phone at 31 20 793 2536 and via email at [email protected]. Learn More on Robert Hershberg's contact information.
Has Robert Hershberg been buying or selling shares of Atai Beckley?: Within the last three months, Robert Hershberg has sold $496,000.00 in shares of Atai Beckley stock. Most recently, Robert Hershberg sold 100,000 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.96, for a transaction totalling $496,000.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company's stock, valued at $496,000. Learn More on Robert Hershberg's trading history.
Who are Atai Beckley's active insiders?: Atai Beckley's insider roster includes Christian Angermayer (Director), Kevin Craig (Chief Medical Officer), Robert Hershberg (Director), Anne Johnson (CFO), Sahil Kirpekar (Insider), Srinivas Rao (Insider), and Gregory Weaver (CFO). Learn More on Atai Beckley's active insiders.
Are insiders buying or selling shares of Atai Beckley?: During the last year, insiders at the sold shares 2 times. They sold a total of 142,579 shares worth more than $708,895.00. The most recent insider tranaction occured on July, 7th when Director Robert Hershberg sold 100,000 shares worth more than $496,000.00. Insiders at Atai Beckley own 26.8% of the company. Learn More about insider trades at Atai Beckley.
Information on this page was last updated on 7/7/2026.

Robert Hershberg Insider Trading History at Atai Beckley

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/7/2026	Sell	100,000	$4.96	$496,000.00	100,000

Robert Hershberg Buying and Selling Activity at Atai Beckley

Atai Beckley Company Overview

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Today's Range

Now: $4.97

$4.81

$5.10

50 Day Range

MA: $4.39

$3.78

$5.36

2 Week Range

Now: $4.97

$2.58

$6.75

Volume

7,855,630 shs

Average Volume

5,979,201 shs

Market Capitalization

$1.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56